Aclaris Therapeutics, Inc. (ACRS)

Market Cap	85.11M
Revenue (ttm)	31.25M
Net Income (ttm)	-88.48M
Shares Out	70.93M
EPS (ttm)	-1.27
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	441,561
Open	1.190
Previous Close	1.190
Day's Range	1.160 - 1.200
52-Week Range	0.590 - 11.120
Beta	0.23
Analysts	Hold
Price Target	11.50 (+858.33%)
Earnings Date	May 10, 2024

About ACRS

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials f...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Oct 7, 2015
• Employees: 86
• Stock Exchange: NASDAQ
• Ticker Symbol: ACRS

Financial Performance

In 2023, ACRS's revenue was $31.25 million, an increase of 5.03% compared to the previous year's $29.75 million. Losses were -$88.48 million, 1.81% more than in 2022.

Analyst Forecast

According to 6 analysts, the average rating for ACRS stock is "Hold." The 12-month stock price forecast is $11.5, which is an increase of 858.33% from the latest price.

Price Target

$11.5

(858.33% upside)

Analyst Consensus: Hold